[go: up one dir, main page]

MX2007013472A - Vacuna. - Google Patents

Vacuna.

Info

Publication number
MX2007013472A
MX2007013472A MX2007013472A MX2007013472A MX2007013472A MX 2007013472 A MX2007013472 A MX 2007013472A MX 2007013472 A MX2007013472 A MX 2007013472A MX 2007013472 A MX2007013472 A MX 2007013472A MX 2007013472 A MX2007013472 A MX 2007013472A
Authority
MX
Mexico
Prior art keywords
hpv
vaccine
protein
delivery
immunogenic fragment
Prior art date
Application number
MX2007013472A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007013472(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0509010A external-priority patent/GB0509010D0/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2007013472A publication Critical patent/MX2007013472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un metodo para la prevencion de la infeccion y/o enfermedad de HPV, el metodo que comprende suministrar una primera vacuna de HPV que comprende una proteina de L1 o fragmento inmunogenico de la misma de por lo menos HPV 16 y HPV 18, y una segunda vacuna de HPV que no comprende los componentes de L1 de HPV 16 y HPV 18 de la primera vacuna, y donde la segunda vacuna comprende una proteina de L1 o fragmento inmunogenico de la misma de por lo menos otro tipo de HPV oncogenico, en donde la primera y segunda vacunas pueden suministrarse en cualquier orden y suministrarse por separado por un intervalo de tiempo adecuado.
MX2007013472A 2005-04-26 2006-04-24 Vacuna. MX2007013472A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67482905P 2005-04-26 2005-04-26
GB0509010A GB0509010D0 (en) 2005-05-03 2005-05-03 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
PCT/EP2006/003918 WO2006114312A2 (en) 2005-04-26 2006-04-24 Vaccine

Publications (1)

Publication Number Publication Date
MX2007013472A true MX2007013472A (es) 2008-04-02

Family

ID=36992675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013472A MX2007013472A (es) 2005-04-26 2006-04-24 Vacuna.

Country Status (12)

Country Link
US (1) US20090181052A1 (es)
EP (1) EP1877086A2 (es)
JP (1) JP2008539184A (es)
KR (1) KR20080005585A (es)
AR (1) AR054259A1 (es)
AU (1) AU2006239422A1 (es)
CA (1) CA2606092A1 (es)
EA (1) EA013326B1 (es)
MX (1) MX2007013472A (es)
NO (1) NO20075194L (es)
SG (1) SG159525A1 (es)
WO (1) WO2006114312A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PE20110327A1 (es) * 2008-07-31 2011-06-29 Glaxosmithkline Biolog Sa Vacuna contra el virus de papiloma humano
AU2009348078B2 (en) * 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
KR102049988B1 (ko) 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
CR20220395A (es) 2020-02-14 2022-10-27 Merck Sharp & Dome Llc Vacuna contra hpv
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
CA3229064A1 (en) 2021-08-19 2023-02-23 Andrew Bett Thermostable lipid nanoparticle and methods of use thereof
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE60336581D1 (de) * 2002-12-20 2011-05-12 Glaxosmithkline Biolog Sa Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
KR20080005585A (ko) 2008-01-14
EP1877086A2 (en) 2008-01-16
WO2006114312A3 (en) 2007-04-05
WO2006114312A2 (en) 2006-11-02
AU2006239422A1 (en) 2006-11-02
CA2606092A1 (en) 2006-11-02
NO20075194L (no) 2008-01-18
JP2008539184A (ja) 2008-11-13
EA200702079A1 (ru) 2008-04-28
US20090181052A1 (en) 2009-07-16
AR054259A1 (es) 2007-06-13
EA013326B1 (ru) 2010-04-30
SG159525A1 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
WO2007030810A3 (en) Multiparameter whole blood monitor and method
UA85536C2 (en) Viral antigens
WO2004080403A3 (en) Influenza virus vaccine
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MY169275A (en) Method of immunization against the four serotypes of dengue
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2006115843A3 (en) Nipah virus vaccines
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2003063899A3 (en) Vaccine adjuvant based on a cd4 0 ligand
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
NO20075194L (no) vaksine
WO2003059385A3 (en) Hiv vaccine and method of use
WO2008150275A3 (en) Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection
WO2004091524A3 (en) Respiratory virus vaccines
AU2003255275A1 (en) Improved anthrax vaccines and delivery methods
WO2003060088A3 (en) Viral vaccine production method
WO2006007555A3 (en) Rotavirus antigens
SI1949913T1 (sl) Imunsko stimulacijska kombinacija za zaĺ äśito in zdravljenje hepatitisa c
TW200716170A (en) Vaccine
NZ512850A (en) Treatment of papillomavirus infections
WO2004006831A3 (en) Method and device for inducing biological processes by micro-organs
SG147465A1 (en) Vaccine
WO2007121491A8 (en) Hcv vaccinations